Decoding RAGE in diabetes: a pathogenic signaling hub modulated by decoy receptors in diabetic complications
Frontiers in Clinical Diabetes and Healthcare · 26.08.2026 · 7
DOI: 10.3389/fcdhc.2026.1854214 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Clinical Diabetes and Healthcare, online erschienen am 26.08.2026. Verfasst von Yupa Srithongchai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes is characterized by chronic hyperglycemia and dyslipidemia, which impose sustained metabolic stress and drive the development of diabetic complications. In this review, we position the axis between advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE) as a central hub that couples metabolic stress to persistent cellular stress and inflammatory responses. Ligand engagement of full-length membrane-bound RAGE (mRAGE) enhances reactive oxygen species (ROS) generation and activates nuclear factor kappa B (NF-κB), establishing a self-amplifying feed-forward loop that promotes RAGE expression, inflammation and further AGE accumulation. RAGE exhibits marked structural heterogeneity: in addition to signaling-competent mRAGE, soluble decoy receptors—including soluble RAGE (sRAGE) produced by ectodomain shedding and endogenous secretory RAGE (esRAGE) generated by alternative splicing—sequester ligands and attenuate downstream signaling. Moreover, RAGE recognizes a broad ligand repertoire beyond AGEs, such as S100 proteins and high-mobility group box 1 (HMGB1), reinforcing its role as an integrator of metabolic and sterile inflammatory cues. Notably, RAGE also mediates physiological transport of oxytocin across the blood–brain barrier (BBB), a process implicated in oxytocin-dependent social behaviors, without activating canonical, pro-inflammatory RAGE signaling. Accordingly, therapeutic strategies should selectively suppress pathogenic, ligand-driven RAGE signaling and/or augment decoy RAGE activity while preserving RAGE-dependent oxytocin transport.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
- Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
Zitieren
APA
Srithongchai, Y., Harashima, A., Munesue, S., Kimura, K., Oshima, Y., Tanaka, M., Takahashi, H., Sakulsak, P., Uramoto, C., Leerach, N., & Yamamoto, Y. (2026). Decoding RAGE in diabetes: a pathogenic signaling hub modulated by decoy receptors in diabetic complications. Frontiers in Clinical Diabetes and Healthcare, 7. https://doi.org/10.3389/fcdhc.2026.1854214
Vancouver
Srithongchai Y, Harashima A, Munesue S, Kimura K, Oshima Y, Tanaka M, et al. Decoding RAGE in diabetes: a pathogenic signaling hub modulated by decoy receptors in diabetic complications. Frontiers in Clinical Diabetes and Healthcare. 2026;7. doi:10.3389/fcdhc.2026.1854214
BibTeX
@article{Srithongchai2026,
author = {Srithongchai, Yupa and Harashima, Ai and Munesue, Seiichi and Kimura, Kumi and Oshima, Yu and Tanaka, Mariko and Takahashi, Hiroya and Sakulsak, Pathitta and Uramoto, Chisato and Leerach, Nontaphat and Yamamoto, Yasuhiko},
title = {Decoding RAGE in diabetes: a pathogenic signaling hub modulated by decoy receptors in diabetic complications},
journal = {Frontiers in Clinical Diabetes and Healthcare},
year = {2026},
volume = {7},
doi = {10.3389/fcdhc.2026.1854214}
}
EUVIMED